Journal: Molecular Therapy Advances
Article Title: Development of bicistronic plasmids and fusion proteins for clinical translation of tumor immune reprogramming
doi: 10.1016/j.omta.2026.201708
Figure Lengend Snippet: Survival in B16-F10 mouse model with antibiotic-gene free NanoP (A) Transfection of B16-F10 cells using 600 ng of pUNO1 or nanoplasmid (NanoP) backbones as determined by flow cytometry. (B) GFP expression, determined by flow cytometry. Each data bar represents mean ± SEM with four biological replicates. (C) Average tumor growth of tumors treated with nanoplasmid 4T12 NPs + anti-PD1 vs. nanoplasmid luciferase NPs + anti-PD1. Each data curve represents eight biological replicates. Significance is represented by ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, and ∗∗∗∗ p ≤ 0.0001.
Article Snippet: In tandem, the pUNO1 backbone from the plasmid pUNO1 MCS (InvivoGen, catalog no. pUNO1-mcs) was digested with NheI and SalI.
Techniques: Transfection, Flow Cytometry, Expressing, Luciferase